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Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) have been
developed and improved as both diagnostic and guidance tools for interventional
procedures over the past three decades. IVUS has a resolution of 100µm with a
high tissue penetration and capability of assessing the entire structure of a coronary
artery including the external elastic membrane, whereas OCT has a higher resolution of
10–20µm to assess endoluminal structures with a limited tissue penetration compared
to IVUS. Recently, two companies, CONAVI and TERUMO, integrated IVUS and OCT into
a single catheter system. With their inherent strength and limitations, the combined IVUS
and OCT probes are complementary and work synergistically to enable a comprehensive
depiction of coronary artery. In this review, we summarize the performance of the two
intracoronary imaging modalities—IVUS and OCT—and discuss the expected potential
of the novel hybrid IVUS–OCT catheter system in the clinical field.
Keywords: intravascular ultrasound, optical coherence tomography, hybrid IVUS–OCT catheter, intracoronary
imaging, vulnerable plaque, percutaneous coronary intervention
INTRODUCTION
History of Intracoronary Imaging Modalities
The history of percutaneous coronary intervention (PCI) started with the first coronary balloon
angioplasty performed by Andreas Grüntzig in 1977 (1). In parallel with the remarkable evolution
of PCI and the development of drug-eluting stents (DESs), the performance of intravascular
imaging devices has been also improved. Figure 1 summarizes the history of both interventional
cardiology and intravascular imaging devices. Intravascular ultrasound (IVUS), as the first
intravascular imaging device, was introduced by Yock et al. in the 1980s (2). Optical coherence
tomography (OCT) was introduced a few years later in the 1990s (3, 4). Although the two
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FIGURE 1 | Timeline of intravascular ultrasound and optical coherence tomography with advances of PCI era. A history focused on intracoronary imaging devices
(IVUS and OCT). Red and blue frames indicate representative events associated with IVUS and OCT, respectively. IVUS, intravascular ultrasound; OCT, optical
coherence tomography; POBA, plain old balloon angioplasty; BMS, bare-metal stent; DES, drug-eluting stent; PCI, percutaneous coronary intervention; ACC,
American College of Cardiology; AHA, American Heart Association; SCAI, Society for Cardiovascular Angiography; ESC, European Society of Cardiology; EACTS,
European Association for Cardio-Thoracic Surgery; MACE, major adverse cardiac events.
devices have the same basic principles and visualize the
intracoronary structures by reconstructing images from signal
waves scattered back from the vessel wall to the catheter, the
utilized signals are different: ultrasound (wavelength 40–50µm)
in IVUS and low-coherence light (wavelength 1.3µm) in OCT
(5, 6). The two modalities of imaging have advantages and
disadvantages, which are described in the next chapter (1-2).
In 1999, the first DES was introduced that lowered the rate of
in-stent restenosis compared to bare-metal stents (BMSs) (7–11).
In the new era of DESs, not only simple lesions but also more
complex lesions were treated by PCI; in this setting, intravascular
imaging has played an important role as a clinical support tool
for planning and assessing the final results of PCI (12, 13). In
the IVUS-XPL trial, Hong et al. demonstrated that usage of IVUS
significantly reduced 1- and 5-year major adverse cardiac events
(MACE; cardiac death, target vessel myocardial infarction [MI],
or ischemic-driven target lesion revascularization) in patients
with long lesions implanted with second-generation DES, which
Abbreviations: 3D, Three-dimensional; ACS, acute coronary syndrome; BRS,
bioresorbable scaffold; BMS, bare-metal stent; CTCA, computed tomography
coronary angiography; DES, drug-eluting stent; EAPCI, European Association
of Percutaneous Cardiovascular Interventions; EEM, external elastic membrane;
ESC, European Society of Cardiology; FFR, fractional flow reserve; IB, integrated
backscatter; IVUS, intravascular ultrasound; KBT, kissing-balloon technique; LAD,
left anterior descending artery; LMCA, left main coronary artery; LMWD, low-
molecular-weight dextran; MACE, major adverse cardiac events; MACCE, major
adverse cardiac and cerebrovascular events; MI, myocardial infarction; MVCAD,
multivessel coronary artery disease; NIRS, near-infrared spectroscopy; OCT,
optical coherence tomography; OFDI, optical frequency domain imaging; PCI,
percutaneous coronary intervention; RF, radiofrequency data; TCFA, thin-cap
fibroatheromas; TVF, target-vessel failure; VH, virtual histology.
proved the efficacy and safety of the usage of IVUS in complex
PCI (14, 15). Moreover, Zhang et al. reported that IVUS-guided
DES implantation significantly reduced target-vessel failure
(TVF: cardiac death, target-vessel MI, or ischemic-driven target
vessel revascularization) at 12 months compared to angiography-
guided DES implantation in the ULTIMATE (Intravascular
Ultrasound Guided Drug Eluting Stents Implantation in “All-
Comers” Coronary Lesions) randomized controlled trial (16).
Those results support the use of IVUS as a PCI guidance tool in
the contemporary PCI era.
In addition to conventional gray-scale IVUS assessment,
analysis of the raw backscattered IVUS radiofrequency (RF)
data can be also utilized for assessments of plaque morphology,
tissue characterization, and vulnerable plaque detection (17).
In 2011, Stone et al. reported the results of the PROSPECT
(Providing Regional Observations to Study Predictors of Events
in the Coronary Tree) study, demonstrating that a large
plaque burden (≥70%) (HR: 5.03, 95% CI: 2.51–10.11) and
a thin-cap fibroatheroma (TCFA) (HR: 3.35, 95% CI: 1.77–
6.36) detected by IVUS-RF as well as a minimal lumen area
<4.0 mm2 (HR: 3.21, 95% CI: 1.61–6.42) were independent
predictors of MACE (cardiac death, cardiac arrest, MI, or
rehospitalization due to unstable or progressive angina) in
non-culprit lesions of patients presented with acute coronary
syndrome (ACS) (18). In this trial, the outcome of MACE
was mainly driven by the incidence of rehospitalization due to
unstable or progressive angina. Thereafter, the ATHEROREMO-
IVUS (European Collaborative Project on Inflammation and
Vascular Wall Remodeling in Atherosclerosis—Intravascular
Ultrasound) study confirmed that the finding of VH-IVUS TCFA
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was independently associated with the composite of death and
ACS (19). Those trials unraveled the importance of assessing
plaque characteristics in a high-risk population, and the efficacy
of IVUS-RF on stratifying cardiovascular risk, apart from clinical
and angiographic characteristics (20).
The first-in-man OCT study was conducted in 2002 (21). In
the ILUMIEN II study, OCT-guided stent implantation showed
comparable stent expansions (defined as the minimal stent area
divided by the mean of the proximal and distal reference lumen
areas) compared to those reported in the IVUS-guided group
of the ADAPT-DES study (72.8 vs. 70.6%) (22). Thereafter,
the ILUMIEN III: OPTIMIZE PCI randomized study showed
a comparative efficacy of OCT-guided PCI with a reference of
IVUS-guided PCI in terms of a post-PCI minimum stent area
(non-inferioritymargin: 1.0mm2, one-sided 97.5% lower CI: 0.70
mm2, p for non-inferiority = 0.001, p for superiority = 0.42)
(23). With regard to clinical outcomes, the OPtical frequency
domain imaging vs. INtravascular ultrasound in percutaneous
coronary InterventiON (OPINION) randomized controlled trial
showed that OCT-guided PCI was not inferior to the IVUS-
guided PCI in terms of TVF (cardiac death, target-vessel MI,
or ischemia-driven target vessel revascularization) at 12 months
follow-up (HR: 1.07, upper limit of one-sided 95% CI: 1.80, p
for non-inferiority = 0.042) (24). The latest European Society of
Cardiology (ESC)/EACTS guidelines updated the indication of
usage of OCT for stent optimization as class IIa recommendation,
corresponding with the same level of recommendation as
IVUS (25).
Recently, the CLIMA study demonstrated that the OCT-
defined plaque vulnerability features (MLA < 3.5 mm2, TCFA,
lipid arc circumferential extension >180◦, and macrophage
findings) in the left anterior descending artery (LAD) were
significantly associated with the increased risk of a composite of
cardiac death and target-segment (LAD)MI at 12 months among
patients undergoing clinically indicated coronary angiography
(HR: 7.54, 95%CI: 3.1–18.6) (26). The results of the CLIMA study
indicated the feasibility and efficacy of OCT for detecting high-
risk plaques leading to adverse events. Further trials such as the
ILUMIEN IV: Optimal PCI trial (NCT03507777) and October
trial (NCT03171311) (27) are expected to further demonstrate
the clinical safety and efficacy of OCT in guiding PCI.
IVUS and OCT have evolved in parallel over the last years.
Recently, however, hybrid IVUS-OCT systems were developed
to merge the advantages of both modalities into a single
catheter (28–30).
This review aims to summarize the differences and
complementary aspects of IVUS and OCT, and describe
the novel hybrid IVUS–OCT catheter systems.
Basic Advantages and Disadvantages of
IVUS and OCT
Although both IVUS and OCT have similarities, it is still
controversial which intravascular imagingmodality is better to be
used as either a diagnostic or guidance tool (6, 31). Multimodality
invasive imaging assessments are not recommended due to the
increased risk of complications and cost. Therefore, operators
should be aware of eachmodality’s advantages and disadvantages,
and select the imaging tool based on the clinical need, location of
the segment of interest, angiographic appearance of the vessel,
lesion characteristics, and operators’ experiences. In fact, a recent
web-based survey suggested that most operators thought to use
each imaging modality (IVUS and OCT) properly depending on
the specific anatomic and patient characteristics (32).
Imaging Acquisition
One of the disadvantages of OCT is the need for blood clearance
during pull-back since the light signal is attenuated by the red
blood cells (6). Blood clearance is achieved by contrast injection.
The total volume of the contrast medium tends to be higher
in OCT-guided PCI than those without OCT. In the ILUMIEN
III: OPTIMIZE PCI study, the contrast volume during the PCI
was significantly higher in the OCT group compared to that
of the IVUS group (median 222 vs. 190ml, p = 0.004) or the
angiography group (vs. 183ml, p = 0.001) (23). Therefore, in
patients with renal impairment, IVUS should be preferred over
OCT (23, 24). Studies suggested alternatives to contrast agents
for blood clearance during OCT pull-back (33), such as low-
molecular-weight dextran (LMWD) to perform “zero-contrast
PCI” (34–37). On the other hand, IVUS does not require blood
clearance, and it has been shown that it canminimize the contrast
volume when compared to angiography-guided PCI (38). In
the ULTIMATE trial, however, IVUS-guided PCI was associated
with significantly higher contrast volume than angiography-
guided PCI (16). Since this paradox was possibly due to longer
procedural time for stent optimization in the IVUS-guided PCI
group, operators should pay attention to the use of contrast
during IVUS-guided PCI as well.
Resolution and Penetration Depth
With respect to the imaging capabilities of intracoronary
imaging, resolution, and penetration depth are recognized
as two important factors (Figure 2). OCT has the highest
resolution among all the contemporary available coronary
imaging modalities (axial 10–20µm and lateral 20–90µm),
which is ∼10 times greater than that of IVUS (axial 100–
150µm and lateral 150–300µm) (4, 39). The higher resolution
of OCT enables more detailed evaluation than IVUS at the
endoluminal level and for the superficial plaque (e.g., in
detecting cavity formation of a plaque rupture, TCFA, and stent
architecture) (40). With regards to its diagnostic performance
of functionally significant stenosis, Ramasamy et al. reported
that OCT has a better accuracy than IVUS in non-left main
stem lesions from the meta-analysis of 33 studies (41). Moreover,
the high resolution of OCT enables the identification of
suboptimal PCI results such as coronary dissections, tissue
protrusions, underexpansion, and stent struts malapposition
more clearly than IVUS (23). Furthermore, also in the long-
term follow-up, OCT can evaluate the neointimal proliferation,
neoatherosclerosis, uncovered struts, persistent/late-acquired
stent malapposition, and/or coronary evagination, which would
be associated with adverse events (42–44). In the consensus paper
from the European Association of Percutaneous Cardiovascular
Interventions (EAPCI) published in 2018, the use of OCT was
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FIGURE 2 | Observational abilities of IVUS and OCT in the settings of several intracoronary structures. IVUS indicates both grayscale IVUS and IVUS with
radiofrequency analysis. IVUS, intravascular ultrasound; OCT, optical coherence tomography; BRS, bioresorbable scaffold; EEM, external elastic membrane.
highly recommended in the case of stent failures sincemost of the
causes of those stent failures could be detected by OCT (45, 46).
In contrast to IVUS, OCT has lower tissue penetration
depth (1–2mm) than IVUS (5–6mm), leading to incomplete
visualization of the vessel wall especially in large vessels, or
in case of an increased plaque burden (47). In this context,
IVUS enables assessment of the deeper layers of the vessel
than OCT, including adventitia. Proper vessel and stent sizing
are important parts for PCI optimization because the under-
or overestimation of the stent size can lead to suboptimal
results or complications such as major coronary dissection,
perforation or extensive malapposition, and underexpansion
(42, 48, 49). In IVUS, the external elastic membrane (EEM)-
based approach for sizing is often used, in which the smallest
EEM diameter in the reference area is recommended as the
stent reference diameter. The approach may not be always
feasible in OCT due to its limited penetration depth. In the
ILUMEN III study, the distal EEM was visible for >180◦ in
76.8% cases by site-assessed and in 95.2% cases by core lab-
assessed (23). The measurement protocol of OCT for reference
stent diameters is expected to be refined in further clinical
studies. By using IVUS, we can assess all layers of interest
of the vessel including vessel remodeling in the follow-up
imaging (50, 51). Radiofrequency assessment or echogenicity
may potentially help in differentiating the components of
plaques (52).
Calcification
Ultrasound is significantly influenced by the presence of calcium;
calcified plaque scatters ultrasound signal, and therefore, the
evaluation of plaque behind calcium is not feasible by IVUS
(53). On the other hand, with OCT, the calcified plaques are
recognized as low-intensity structures with clear demarcation
of the calcific tissue borders (54). In the context of clinical
implication, Maejima et al. reported that a calcium arc below
227 degrees and a calcium thickness below 670µm would
suggest the use of cutting/scoring balloons (55). Recently, an
OCT-based calcium scoring system was developed to predict
stent underexpansion (56). The calcium score is composed of
maximum angle of >180◦ (2 points), maximum thickness of
>0.5mm (1 point), and length of >5mm (1 point). The calcium
score of 4 was significantly associated with stent underexpansion
when compared to a score of 0–3 (78 vs. 96%, p < 0.01),
suggesting heavily calcified lesions that need debulking.
Three-Dimensional Reconstruction
Online three-dimensional (3D) reconstruction is one optional
advantage of OCT. It can assist in understanding the complex
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structures in some specific cases (e.g., a stent fracture), which is
difficult to be detected in cross-sectional two-dimensional images
(57–60). Although a 3D reconstruction image is also possible in
IVUS, the tedious segmentation process and its poor resolution
that does not allow sufficient strut-level assessment render IVUS
an unattractive modality of 3D vessel modeling (61, 62).
Physiological Assessment
Recently, physiological assessment of lesion severity was
attempted by processing IVUS and OCT data using
computational modeling (63–67). The accuracy of these
approaches strongly depends on the accuracy of the 3D imaging
models. Therefore, OCT-derived fractional flow reserve (FFR)
might be superior to IVUS-derived FFR or angiography-derived
FFR. Although the clinical implication of these approaches
still needs further validation, they may have the potential to
enable a comprehensive assessment of the characteristics of a
lesion and its hemodynamic severity using a single imaging
technique (68–70).
Bioresorbable Scaffold Implantation
In the treatment with bioresorbable scaffold (BRS), intravascular
imaging played a major role in facilitating precise implantation
of the device, which has thick and wide struts. OCT would be
clinically more applicable for the optimized implantation than
IVUS because the polymeric struts of BRS are scarcely visible
by IVUS. Although the novel 60-MHz IVUS acquires higher-
resolution (axial resolution <40µm) images than conventional
IVUS (71), it is still inferior to OCT in terms of visualization
of BRS struts (72, 73). In PCI with BRS, the importance of an
optimized implantation technique, the so-called PSP (prepare
the lesion, sizing appropriately, and post-dilation), has been
suggested to avoid clinical adverse events (74–76). Intravascular
imaging is mandatory to fulfill these PSP criteria during PCI
(77). OCT can provide a clear visualization of BRS struts, but
it is unable to assess all vessel layers due to its low penetration
depth. IVUS allows the visualization of the entire vessel wall
enabling the calculation of its eccentricity and symmetry indices
and the evaluation of vessel remodeling that subsequently occurs
after BRS implantation. Serruys et al. demonstrated that BRS
implantation was associated with a higher incidence of expansive
remodeling and late lumen enlargement at 3 years compared
to metallic stents in the ABSORB II trial (51). Although this
favorable effect was not consistent in other ABSORB trials (78),
it will be important to assess remodeling patterns at long-term
follow-up after the full absorption of the deployed scaffolds.
Coregistration of IVUS and OCT
Several studies attempted to fuse IVUS andOCT images obtained
by two different imaging catheters in a serial fashion and showed
the synergistically high potential of multimodality imaging for
the evaluation of plaque composition, but they also suggested
the limitation to acquire strict coregistration images by separate
two pullbacks (79, 80). To fuse IVUS and OCT images with two
separate acquisition, it is necessary to detect several landmarks
such as side branches and calcifications (81). Thereafter, it also
takes time and effort to combine the two imaging modalities into
a single image, a fact that makes impossible the broad application
of this approach in research. A hybrid IVUS–OCT catheter
system is warranted to enable accurate online coregistration and
fusion of high-quality images obtained by the two imaging probes
during a single pull-back.
RECENT ADVANCES OF IVUS AND OCT,
AND DEVELOPMENT OF THE HYBRID
CATHETER
Development of a Hybrid IVUS–OCT
Catheter
The first combined IVUS–OCT catheter was designed by Li
et al. (28) and Yin et al. (30) and tested in a healthy rabbit
aorta. However, the prototype had limitations that did not
allow its use in clinical practice; the catheter was too large
with a maximum outer diameter of 2.4mm (7.2 Fr.); it did
not allow the accurate coregistration of the OCT and IVUS
images, and the generated IVUS images had increased noise
due to electromagnetic interference by the motor (29, 30). In
2011, Yin et al. reported a modified combined miniaturized
OCT–IVUS probe (82). The outer diameter was reduced to
0.69mm, which fit in a 3.6 Fr. (1.18mm) catheter sheath; this
was achieved by arranging the position of the OCT probe and the
IVUS transducer to longitudinal offset (sequential arrangement:
Figure 3C). They tested the IVUS–OCT system in vitro in
a human coronary artery specimen and in vivo in a rabbit
abdominal aorta and a swine coronary artery (83).
Li et al. introduced another hybrid IVUS–OCT system in 2012
(84). They developed a coplanar IVUS–OCT hybrid catheter
with a maximum outer diameter of 1.33mm (4 Fr.) including
the catheter sheath, allowing a more accurate simultaneous
coregistration of IVUS and OCT compared to the sequential
IVUS–OCT system (Figure 3B), even in the presence of cardiac
motion. Validation of the prototype using human coronary
arteries demonstrated improved good tissue characterization
and plaque feature identification using histology as the gold
standard. A variant IVUS–OCT probe with a shorter length of
the rigid part of the catheter tip of 1.5mm was shown by Li
et al. and Ma et al. in 2013 (85, 86). That model had a back-
to-back arrangement (Figure 3A) and allowed image acquisition
at a higher frame rate of 20 fps compared to past models. In
2015, Li et al. showed an advanced IVUS–OCT prototype that
acquired IVUS–OCT images with a frame rate of 72 fps, enabling
assessment of a 72-mm coronary artery segment in 4 s; the
prototype was validated in vivo in the aortas of atherosclerotic
rabbits and ex vivo in cadaveric human coronary arteries (87). In
2018, the first clinical use of the hybrid IVUS–OCT catheter was
reported by Sheth et al., showing beautiful coregistered images
with clinically acceptable specifications with respect to the size,
speed, and resolution.
CONAVI: The Novasight Hybrid System
The Novasight HybridTM System was developed by Conavi
Medical Inc. (Toronto, Canada) and researchers at the University
of Toronto (Figure 4). The product specifications are shown in
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FIGURE 3 | Various types of arrangements of IVUS and OCT transducer. There were three types of arrangements of IVUS and OCT transducer; (A): back-to-back
arrangement; (B): coplanar arrangement; (C): sequential arrangement; (D): colinear arrangement. The colinear arrangement can acquire the strictest coregistration
image of IVUS and OCT in three types of arrangements. IVUS, intravascular ultrasound; OCT, optical coherence tomography.
FIGURE 4 | CONAVI Novasight hybrid imaging catheter; external appearances. (A) A whole appearance of system body. (B) Interface module. (C) Catheter technical
specifications. (D) The transducer. IVUS, intravascular ultrasound; OCT, optical coherence tomography.
Table 1. The catheter has a 1.7 Fr. tip and a 2.8 Fr. imaging
window distally (3.3 Fr. catheter shaft for the proximal and
middle sections of the catheter), and is compatible with a
0.014-inch guidewire. Colinear imaging design with overlapping
IVUS and OCT was adopted (Figure 3D), which allows the user
to visualize the vessel wall with both modalities at the same
time and to inherently acquire accurately coregistered images
(Figures 5A,B). Lumen or vessel size can be measured based
on both IVUS and OCT cross-sectional images (Figure 5C).
Pullback speed can be selected from 0 (manual control), 0.5,
1.0, 5, 10, and 25 mm/s with a maximum pullback length
of 100mm. In case of standalone IVUS imaging, the frame
rate is 30 or 100 fps. In case of combined IVUS and OCT
imaging, the pullback will be performed with a frame speed
of 100 fps after blood clearance. The system does not have a
setting that allows for the acquisition of OCT only, as there is
little, if any, anticipated disadvantage to collecting IVUS at the
same time. The maximum field of view radius is 6mm derived
from IVUS.
The first clinical usage was reported by Sheth et al. in
2018 (88). In that case, the Novasight system could provide
coregistered and co-aligned IVUS and OCT images in a patient
with recent ST-segment elevation MI (STEMI) followed by
PCI for a non-culprit lesion of the LAD. Lipid-rich plaques,
bifurcations, and deeply embedded tissues were more clearly
identified by IVUS images than OCT, whereas calcifications,
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TABLE 1 | The specifications of CONAVI Novasight Hybrid and TERUMO Dual
Sensor system.
CONAVI Novasight TERUMO Dual sensor
Compatible wire
size
0.014 inch 0.014 inch
Imgaging window
profile
2.8 Fr. 2.6 Fr.
Catheter shaft
profile
3.3 Fr. 3.2 Fr.
Usable length 149 cm 137 cm
Length from tip to
sensor
12mm 25mm
IVUS OCT IVUS OCT
Frequency 40 MHz 1,310 nm 40MHz 1,300 nm
Axial resolution NA 200µm 15µm
Lateral resolution NA 200µm 30µm
Frame rate -
Single use
30 fps NA 30 or 100 fps 160 fps
Frame rate -
Hybrid use
100 fps 100 or 160 fps
Pullback speed
(mm/sec)
0.5, 1, 5, 10, 25 0.5, 1, 2, 3 at 30
fps, 10 at 100 fps
0, 10, 20, 30, 40
For hybrid use, 0, 10, 20 at 100 fps,
0, 10, 20, 30, 40 at 160 fps










IVUS, intravascular ultrasound; OCT, optical coherence tomography; RF, radiofrequency
backscatter; IB-IVUS, integrated-backscatter IVUS; 3D, three dimensional; NA, not
applicable.
stent struts, and fine dissections were more clearly identified by
OCT imaging.
The Novasight system is currently FDA 510(k) cleared and has
Health Canada approval. A prospective observational study using
the Novasight hybrid imaging catheter has been completed and
demonstrated its feasibility and efficacy for diagnostic purposes
and PCI guidance in 20 patients with a chronic coronary
syndrome or ACS (NCT03484975).
TERUMO: The Dual Sensor
The Dual Sensor hybrid IVUS–OCT catheter system is developed
by TERUMO (Tokyo, Japan) by merging IVUS and optical
frequency domain imaging (OFDI) probes, which are already
clinically available and incorporated in the AltaView (PMDA
approval) and FastView (PMDA and CE mark approval),
respectively. A sequential arrangement of an IVUS transducer
and optical lens with the distance of ∼0.3mm is adopted
(Figure 3C). The catheter is compatible with a 0.014 guidewire
and has a diameter 2.6 Fr. (3.0 Fr. catheter shaft) (Figure 6).
The preliminary product specifications are shown in Table 1.
The IVUS probe has an axial resolution of 120µm, while the
OCT has an axial resolution of 20µm (Figures 7A,B). The
high frame rate of 100 or 160 fps enables a pullback speed
of up to 40 mm/s (0, 10, 20, 30, and 40 mm/s) and studied
segments with a length of 150mm on IVUS and OCT. The image
acquisition method of the simultaneous coregistration of IVUS
and OCT is the same as that of OCT. The acquired images will
be shown not only side by side but also in one fusional image of
IVUS and OCT (Figure 7C). Integrated-backscatter IVUS (IB-
IVUS) analysis will also be available, which will offer further
information about tissue and plaque characteristics (Figure 7D).
Online OFDI 3D reconstruction will facilitate comprehensive
evaluation of complex coronary artery structures.
The device has been tested in postmortem coronary arteries,
and its output was compared to contemporary IVUS as well as
OCT (Figure 7). In this hybrid catheter, IVUS or OCT can be
separately used. Operators can select those functions according
to circumstances during the procedure. For instance, in a case
of left main coronary artery disease, the operator can use the
IVUS function for the purpose of assessing the severity and
guide treatment (25), whereas OCT can be utilized to assess the
final results and detect and treat underexpansion/malapposition
and/or carina shift in the bifurcation (57, 89, 90). The cost is
expected to be similar to that of OFDI.
POTENTIAL CLINICAL APPLICATION OF A
HYBRID IVUS–OCT CATHETER
For Detecting “High-Risk Plaques”
Acute coronary syndrome (ACS) remains one of the leading
causes of death even in the contemporary era (91). It’s well-
known that, in most cases, myocardial infarction can be caused
not by the gradual progression of stenosis, but by a sudden
thrombotic occlusion (92). Virmani et al. reported three major
distinct processes of ACS in histopathological studies, which are
plaque rupture, erosion of intima, and calcified nodule (93, 94).
Among those, plaque rupture occurring in lesions with a TCFA
phenotype is the most frequent cause of ACS and is responsible
for 60–70% of all ACS (94). Intensive medical therapies (e.g.,
aggressive LDL cholesterol lowering) and/or intensive lifestyle
changes can improve the outcomes of the patients with high-risk
plaques (95–98).
TCFA is recognized as a plaque with a necrotic core and
an overlying thin fibrous cap with thickness of <65µm that
contains macrophages and smooth muscle cells (99). Narula
et al. reported in a postmortem study that plaques with fibrous
caps thicker than 84µm are stable plaques, and that in the
majority of the cases, the cap thickness in TCFA ranged
between 54 and 84µm (100). In any case, the evaluation
of TCFA would be technically challenging by grayscale IVUS
because of its limited spatial resolution of 100–150µm, which
exceeds the thickness of TCFA (101). Radiofrequency analysis
of IVUS (RF-IVUS, e.g., virtual histology IVUS [VH-IVUS]
by Philips Healthcare) appears more accurate than grayscale
IVUS in detecting plaque components. A classification scheme
has been proposed to define plaque phenotypes and detect
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FIGURE 5 | CONAVI Novasight hybrid imaging catheter; sample images. (A) Coregistered intracoronary images of superficial atheroma in IVUS (A-1) and OCT (A-2),
and corresponding histopathology (A-3). (B) Preclinical in vivo images. (C) Measurements of lumen size by the coregistered image of IVUS and OCT. By default, any
measurements (areas, distances) made in an IVUS image are automatically copied over into the OCT image and vice versa. The copied measurement can be
removed. IVUS, intravascular ultrasound; OCT, optical coherence tomography.
FIGURE 6 | TERUMO hybrid IVUS–OCT catheter system; external appearances. (A) A whole appearance of system body. (B) Interface module. (C) Catheter
technical specifications. IVUS, intravascular ultrasound; OCT, optical coherence tomography.
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FIGURE 7 | TERUMO hybrid IVUS–OCT catheter system; sample images. (A) Coregistered intracoronary imaging of thrombus in IVUS (A-1) and OCT (A-2) in a
cadaver coronary artery. (B) Coregistered intracoronary imaging of calcification in IVUS (B-1) and OCT (B-2) in a cadaver coronary artery. (C) Fusion image of IVUS
and OCT. (D) IB-IVUS image with OCT. IVUS, intravascular ultrasound; OCT, optical coherence tomography; IB, integrated backscatter.
TCFA using the RF-IVUS estimations and has been extensively
used in prospective studies of coronary atherosclerosis (102).
Similar to the previously mentioned PROSPECT (18) and
ATHEROREMO-IVUS trials (19), the VIVA (VH-IVUS in
Vulnerable Atherosclerosis) study also showed that VH-IVUS
TCFA was significantly associated with the increased risk of
MACE (103).
On the other hand, OCT has the highest spatial resolution
(axial resolution 15–20µm) among intracoronary imaging
devices, which enables the precise measurement of the
cap thickness (104–106). OCT has been well-validated,
and its estimations correlated well with the corresponding
pathophysiological findings (107, 108). Furthermore, some
studies reported that the OCT-detected TCFA was also clinically
associated with the future occurrence of MACE (26, 109, 110).
However, OCT also has limitations as it has poor tissue
penetration. In addition, the OCT signal is attenuated by
lipid tissue and macrophages (111). Therefore, OCT can often
misclassify fibrotic rich plaques with increased superficial
macrophage accumulations as TCFA. In addition, OCT cannot
assess the plaque burden in lipid-rich plaques, which is a strong
predictor of worse outcomes (18, 19, 103).
The quantitative analysis of plaque burden would be well-
assessed by IVUS, especially by IVUS-RF analysis. Recently,
near-infrared spectroscopy intravascular ultrasound (NIRS-
IVUS) was introduced to more accurately detect lipid core
plaques (112–114).
Several previous studies reported the great benefit of the
combined use of OCT and VH-IVUS for detecting TCFA
compared to the single use of either OCT or VH-IVUS (107,
111, 115). Nakano et al. showed that the combined use of IVUS-
RF and OCT gave the highest performance to detect TCFA
(area under the curve [AUC] 0.93, 95% CI 0.85–1.00) compared
with standalone OCT (AUC 0.88, 95% CI 0.76–0.99) or RF-
IVUS (AUC 0.82, 95% CI 0.68–0.95) in the ex vivo autopsy
study (116). Futures studies are expected to examine the efficacy
of the combined IVUS–OCT imaging catheters in detecting
vulnerable plaques.
In addition, wall shear stress would play an important
role in both a plaque progression and a plaque rupture
(117–119). In the assessment of wall shear stress, the fusion
of intracoronary imaging data and coronary angiography or
computed tomography coronary angiography (CTCA) is needed
to make a high-resolution coronary artery model (120–122).
The consensus paper on the assessment of wall shear stress
stated that studies aiming to investigate the effect of wall
shear stress on plaque progression and changes in plaque
composition should preferably create coronary artery models
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using the fusion of IVUS/NIRS-IVUS and coronary angiography
or CTCA (123, 124). On the other hand, studies aiming to
investigate the influence of the local wall shear stress on plaque
microcharacteristics should preferably create the 3D lumen using
the fusion of OCT and biplane angiography or CTCA (125).
The hybrid IVUS–OCT catheter also could allow one to make
a more accurate coronary artery model and may provide new
insight into the association between wall shear stress and a
plaque progression/regression.
Imaging During PCI and Stent Optimization
Although the routine use of intracoronary imaging is not
currently recommended to guide PCI in simple lesions, it
appears to be useful for optimizing PCI results in several
clinical settings. The consensus document from the EAPCI
recommended the use of intracoronary imaging in the setting
of ACS, left main coronary artery (LMCA) disease, two stents
bifurcation, implantation of bioresorbable scaffold, and patients
with renal dysfunction (for IVUS) (45, 46). In the current
ESC/EACTS guidelines of myocardial revascularization, the use
of IVUS or OCT to optimize stent implantation is recommended
in selected patients as Class IIa indication (25).
Hybrid IVUS–OCT catheters have a high potential to support
procedures in a wide range of circumstances by its high
diagnostic efficacy derived from the combination of the two
imaging modalities. Therefore, the hybrid catheter is expected
to be widely utilized in daily clinical practice. In the following
section, we describe the potential value of this hybrid catheter
in guiding PCI in the most challenging lesions such as LMCA
disease and multivessel coronary artery disease (MVCAD).
Hybrid IVUS–OCT Catheter for Left Main
Coronary Artery Disease
LMCA disease can involve either the ostium or the main vessel
or its bifurcation; the left main stem supplies with blood most
of the myocardium, and thus, treatment failure can lead to
critical peri-procedural complications during PCI (126–129). In
the EXCEL trial, PCI was non-inferior to CABG in terms of
the primary endpoint (all-cause death, stroke, or MI) at 3 years
(HR: 1.00, 95% CI 0.79–1.26) (128) and at 5 years (HR: 1.19,
95% CI 0.95–1.50) (130) in patients with LMCA disease and low
or intermediate SYNTAX scores. Of note, the rate of ischemia-
driven revascularization was significantly higher in the PCI arm
than in the CABG arm at 5 years (16.9% in the PCI arm and 10.0%
in the CABG arm, HR: 1.84, 95% CI 1.39–2.44). Although IVUS
guidance was strongly recommended in this trial, it was used only
in 77.2% of the cases in the PCI arm.
Intravascular imaging is useful in assessing the stenosis
severity and guiding PCI in patients with LMCA disease. As a
threshold for revascularization, a minimum lumen area (MLA)
of <6.0 mm2 by IVUS has been recommended (131), which
nearly corresponded to an FFR of <0.80 in Western countries
(25, 132), whereas in the Asian population, the threshold of
MLA is relatively smaller (4.5–4.8 mm2) compared to that
of the Western population (133, 134). The sub-analysis of
the MAIN-COMPARE (Revascularization for Unprotected Left
Main Coronary Artery Stenosis: Comparison of Percutaneous
Coronary Angioplasty vs. Surgical Revascularization) registry
clarified the favorable outcomes of IVUS-guided PCI compared
to angiography-guided PCI in patients with unprotected LMCA
disease (126). Hernandez et al. also demonstrated that the use
of IVUS significantly reduced MACE compared to those of PCI
without IVUS guidance in a registry study (127).
On the other hand, the value of OCT in LMCA disease
is still unclear. The ESC/EACTS guideline of myocardial
revascularization recommended only IVUS for the assessment of
the severity and treatment optimization in LMCA disease (class
IIa indication), whereas OCT is not mentioned regarding LMCA
disease (25). OCT-guided PCI seems to be less feasible for LMCA
disease than IVUS because of the large vessel diameter and the
limited penetration depth of OCT. Moreover, blood clearance
can be sometimes difficult especially in proximal LMCA disease.
Nevertheless, it has to be acknowledged that OCT usage may
have some advantages. OCT in LMCA bifurcation PCI can assess
acute incomplete stent apposition (ISA) after stent implantation
followed by the kissing-balloon technique (KBT) (57, 135). In
order to avoid the so-called “metal carina,” the re-crossing wire
following stent implantation should pass through the most distal
cell of the stent on the jailed side-branch ostium in most cases.
OCT, especially 3D reconstruction, can show stent struts in detail
with a high resolution (89). In the OPTIMUM trial, Onuma
et al. reported that 3D OCT-guided PCI and re-crossing through
the optimal strut cell after stent implantation followed by KBT
significantly reduced acute ISA at the bifurcation compared to
angiography-guided PCI (19.5 vs. 27.5%, p = 0.008) in patients
with bifurcation lesion including LMCA disease (preliminary
data) (136, 137). In addition, final stent optimization excluded
the possibility of stent distortion, or stent underexpansion can
be assessed easier in OCT that has a much higher resolution
than IVUS. Furthermore, OCT-derived FFR can be utilized in the
future to evaluate lesion severity and the residual ischemic risk
after the procedure (69, 70).
By using hybrid IVUS–OCT systems, we can use each function
according to the process comprehensively. For example, OCT
will be utilized for re-crossing wire, the final stent optimization,
and/or physiologically assessments, while IVUS will be utilized
for the indication, the stent/balloon sizing, and/or deciding the
location of the stent landing zone.
Hybrid IVUS–OCT Catheter for Multivessel Coronary
Artery Disease
With regards to multivessel PCI, IVUS-guided PCI is
recommended as Class IIa indication in the latest ESC/EACTS
guideline of myocardial revascularization (25). In the SYNTAX II
trial, recent technical and procedural developments significantly
improved clinical outcomes in terms of 1-year major adverse
cardiac and cerebrovascular events [MACCE (composite
of all-cause death, cerebrovascular event, any MI, and any
revascularization)] compared to those of the PCI arm of the
original SYNTAX-I trial (HR: 0.58, 95% CI 0.39–0.85), and
those outcomes were equivalent to those of the CABG arm of
the original SYNTAX-I trial (HR: 0.91, 95% CI 0.59–1.14), in
patients undergoing multivessel PCI (138, 139). The difference
in the results between SYNTAX-I and -II trials should be
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attributed to the differences in the treatment strategies between
the SYNTAX II trial and the SYNTAX-I trial. In summary, there
are six differences between the two studies: patient selection
based on the SYNTAX II score, physiological assessment of
stenotic lesion, use of intracoronary imaging for complex
procedures, PCI of chronic total occlusion performed by an
expert, use of current-generation DES, and optimal medical
treatment before/after PCI (140). In other words, PCI could
become equivalent to CABG only in cases fulfilling these
criteria in the field of MVCAD, and the use of an intracoronary
imaging is mandatory in this setting. MVCAD often shows
a mixture of various types of lesions (e.g., with bifurcation
lesion, severe calcification, and/or lipid-rich plaques); therefore,
different strategies might be required according to each lesion
characteristic. The hybrid IVUS–OCT will be able to assist
operators to tailor treatment strategy according to lesion types.
In addition, intracoronary imaging-derived FFR may be used
to assess lesion severity and identify those that need treatment,
and estimate the residual ischemic risk after stent implantation,
which is also one component of “best practice PCI” for MVCAD.
LIMITATION
Despite the fact that many interventional cardiologists are aware
of the potential prognostic and clinical value of intravascular
imaging-guided PCI, the application of intravascular imaging
is still low in recent clinical practice especially in Western
countries (141). According to a web-based survey (141), the
most common reason for the underuse of intravascular imaging
is its high cost (65.9%), followed by the prolongation of the
diagnostic procedure or intervention (35.0%), albeit risk of
complications (9.5%) and absence of established clinical value
(8.3%) were, overall, the least commonly reported limiting
factors. However, it was also reported that IVUS-guided PCI
could contribute to the favorable incremental cost-effectiveness
compared to angiography-guided PCI in the dedicated economic
analysis (142).
The hybrid catheter has a marginal incremental cost to
build relative to a single modality imaging catheter that would
not greatly impact the overall cost-effectiveness of intravascular
imaging. The consoles and patient interface modules have
costs that are associated with supporting ultrasound electronics
as well as the optical components for OCT, and thus have
a more noticeable, yet still modest, incremental cost over
single modality systems to provide this advanced dual modality
imaging capability.
For the purpose of detecting a high-risk plaque, a recent
LRP trial demonstrated the impact of a Lipid Core Burden
Index derived from NIRS-IVUS on future cardiac events, which
was independent of intravascular ultrasound plaque burden
or minimum lumen area (113). Further clinical trials will be
needed to compare the hybrid IVUS-OCT system vs. NIRS-
IVUS in terms of the prognostic performance in patients
at risk.
CONCLUSION
Although the routine use of intravascular imaging is not
currently recommended (143), its use is expected to reduce
events in complex PCI. Moreover, in the era of emerging
novel pharmacotherapies, a meticulous evaluation of plaque
morphology would be required to discriminate the potential
population in need (144). The hybrid IVUS–OCT systems have
the potential to assess plaque morphology and PCI results.
“IVUS or OCT, which should be used?”—this question has been
frequently repeated up to now (6, 145). The hybrid IVUS–OCT
system could be the answer in the near future.
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